Cyxone investigates listing on Nasdaq Main Market Nordic Small Cap
Cyxone (publ), a Swedish biotech in autoimmune diseases, announce today that the company investigates a future listing on Nasdaq Main Market Nordic Small Cap. Cyxone is since 2016 listed on Nasdaq First North Growth Market.A listing on Nasdaq Nordic Small Cap would provide conditions for improved liquidity in the share, increase the attention from international analysts, and for institutional investors to consider investing in Cyxone. The company is presently improving procedures and quality regarding the company’s information flow and activities. ContactOla Skanung, interim CEO & CFO